Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).


CSE:RVV - Post by User

Comment by 1ottrunneron Jan 24, 2022 12:52pm
205 Views
Post# 34353637

RE:All stocks take a bath….

RE:All stocks take a bath….
TFTheygonnasay wrote:

from my DD Rvv's bucc works best at mitigating the symptoms and secondary effects of the virus like inflammation. The more big Pharma Attempts to attack the virus itself the worse the virus will get. 



From your DD?

There is absolutely ZERO DD available regarding Bucillamine having some benefit in the COVID indication in any way. Only hype and conjecture.

The company has thus far not presued having the study unblinded. At 700 plus patients there should be enough data to unblind the study.

UNLESS the data is too close to call.

If the data is too close to call its a failure.

The Psilocybin industry in Canada (I realize you said the Canadian market has no value) is about to take off. It is this market, not covid hype, that pushed RVV to its high just over a year ago.

If anyone wants to look into the most likely value of this company, Psilocybin is where is lies.

FYI, I'm currently buying, I've added ~250k shares since the stock fell below .30 and will continue to purchase. I still see this having about 10% to the absolute floor of .24 cents.  That said I am willing to risk the downside below 30 cents.

The possiblity of being able to sell shares for profit at this level is pretty much guaranteed.

IMO


<< Previous
Bullboard Posts
Next >>